Corcept Therapeutics Inc. said its board approved the repurchase of up to $100 million of the company's common stock.

The Menlo Park, Calif.-based pharmaceutical company said the share buyback program will remain in effect until June 30, 2019, unless terminated earlier.

Corcept added that the timing and amount of any repurchases will be based on market conditions, stock price and other factors.